CSF3R and atypical chronic myeloid leukemia, BCR-ABL1 negative: Given the genetic polymorphism of CSF3R and its involvement in the JAK−STAT signaling pathway, JAK inhibitors (e.g., fedratinib and ruxolitinib) have garnered significant attention for the treatment of aCML.